LONDON -- AstraZeneca
(AZN) shares have jumped 15 percent in early trading after Pfizer
(PFE) publicly disclosed details of a $100 billion bid approach.
PfiZer, the maker of Viagra, said Monday that AstraZeneca rejected an initial approach in January valuing the company at about 59 billion pounds ($100 billion). The cash and shares deal would represent a 30% premium on AstraZeneca's closing share price of 35.26 pounds on Jan. 3, the date of the offer.
Pfizer remains interested and is confident a combination is possible.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts